bioMérieux: FilmArray growth prospects intact, it is all about value added
BUY, Fair Value EUR122 (+7%))
The sustainability of FilmArray growth prospects was the centre of interest during the group meeting with Alexandre Mérieux, bioMérieux’s CEO. This seems intact as highlighted by 1/ clinical value-added of FilmArray (depicted in several 2016 ASM’s abstracts) which is increasingly echoed by clinicians, 2/ a good performance by the respiratory panel accounting for 80% of FilmArray sales and 3/ ramp-up of other panels both in the US and in Europe (Japan as free upside). The tougher US reimbursement framework does not impact BIM.
For more information please contact email@example.com